<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109078</url>
  </required_header>
  <id_info>
    <org_study_id>DJT1116PG-DM-107</org_study_id>
    <nct_id>NCT05109078</nct_id>
  </id_info>
  <brief_title>ADME Study of [14C]- Rongliflozin in Healthy Male Subjects</brief_title>
  <official_title>Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]- Rongliflozin in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]- Rongliflozin&#xD;
      in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative excretion of 14C-labeled drug-related material (radioactivity in urine and fecal samples)</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in urine and feces.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the Proportion of different metabolites to determine biotransformation pathway of Rongliflozin</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Proportion of different metabolites(Rongliflozin and main metabolites).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of radioactivity in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma</measure>
    <time_frame>up to 11 days</time_frame>
    <description>Radioactivity concentration in whole blood and plasma samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitive analysis of the concentrations of Rongliflozinand main metabolites in plasma using the validated liquid chromatography-tandem mass spectrometry(LC-MS/MS) to obtain pharmacokinetic data</measure>
    <time_frame>up to 11 days</time_frame>
    <description>The concentrations of Rongliflozin and main metabolites in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Adverse events assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Adult Male Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]- Rongliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of [14C]- Rongliflozin (Suspension, 50mg/100μCi)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]- Rongliflozin</intervention_name>
    <description>Patients will receive single dose of orally [14C]- Rongliflozin on Day 1</description>
    <arm_group_label>[14C]- Rongliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males, 18 to 45 years at the time of screening.&#xD;
&#xD;
          2. Go to Weight&gt;50 kg, Body mass index (BMI) is 19~26 kg/m2&#xD;
&#xD;
          3. Signing of informed consent&#xD;
&#xD;
          4. Participants are able to communicate well with the investigators and be able to&#xD;
             complete the trial according to the Process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical examination, routine laboratory tests, 12-lead ECG, Chest X-ray, abdominal&#xD;
             B-ultrasound, New Coronavirus Testing and other is abnormal and clinically&#xD;
             significant.&#xD;
&#xD;
          2. Positive testing for HIV, HBsAg, HBeAb, HCVAb or Syphilis antibody.&#xD;
&#xD;
          3. CYP3A4, uridine diphosphoglucuronyl transferase(UGT) inducers or inhibitors, and P-gp,&#xD;
             breast cancer resistance protein(BCRP) Substrates were taken within 28 days before&#xD;
             screening.&#xD;
&#xD;
          4. Use of any prescription or over-the-counter drug, any vitamin product, health care&#xD;
             drug or Chinese herbal medicine within 14 days prior to screening.&#xD;
&#xD;
          5. Participants who have participated in any clinical trials within 3 months prior to&#xD;
             screening and have used thetest drug or medical devices.&#xD;
&#xD;
          6. Participants who have been vaccinated within 1 month before screening or plan to be&#xD;
             vaccinated during the trial period.&#xD;
&#xD;
          7. A history of any clinically serious illness or condition, including but not limited to&#xD;
             circulatory, endocrine, nervous,digestive, urinary, or blood, immune, mental, and&#xD;
             metabolic diseases, that the investigator considers to be likely to affect the results&#xD;
             of the study.&#xD;
&#xD;
          8. People who have had heart disease such as heart failure, angina pectoris, myocardial&#xD;
             infarction, and clinically significant arrhythmia.&#xD;
&#xD;
          9. A history of urinary tract infection or repeated hypoglycemia.&#xD;
&#xD;
         10. Participants who had undergone major surgery or whose surgical incision was not&#xD;
             completely healed within 6 months before the screening period;Major surgery includes,&#xD;
             but is not limited to, any surgery with a significant risk of bleeding, prolonged&#xD;
             general anesthesia, or an open biopsy or significant traumatic injury.&#xD;
&#xD;
         11. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred withini&#xD;
             6 months before screening.&#xD;
&#xD;
         12. Significant clinical bleeding symptoms or definite bleeding tendency occurred within 3&#xD;
             months before screening.&#xD;
&#xD;
         13. Hemorrhoids or perianal diseases with regular/bleeding in the stool; Patients with&#xD;
             gastrointestinal dysfunction, such as irritable bowel syndrome and inflammatory bowel&#xD;
             disease, may be affected by drug absorption as determined by researchers.&#xD;
&#xD;
         14. Participants who have allergies or have special dietary requirements and cannot follow&#xD;
             the standard diet.&#xD;
&#xD;
         15. Habitual constipation or diarrhea.&#xD;
&#xD;
         16. Heavy drinking or regular drinking in the six months preceding the screening period,&#xD;
             or alcohol breath test results ≥20 mg/dL during the screening period.&#xD;
&#xD;
         17. Those who had smoked more than 5 cigarettes per day on average in the 3 months before&#xD;
             the screening period or habitually used nicotine-containing products and were unable&#xD;
             to quit during the test period.&#xD;
&#xD;
         18. Substance abuse or use of soft drugs (e.g., marijuana) in the 3 months prior to the&#xD;
             screening period or use of hard drugs (e.g., cocaine, amphetamines,&#xD;
             phenylcyclohexidine, etc.) in the 1 year prior to the screening period, or screening&#xD;
             for positive urine drug abuse (drug) tests.&#xD;
&#xD;
         19. Habitual consumption of grapefruit juice or excessive consumption of tea, coffee&#xD;
             and/or caffeinated beverages and failure to abstain during the study period.&#xD;
&#xD;
         20. Those with a history of fainting needle or blood, have difficulty in blood collection&#xD;
             or cannot tolerate vein puncture for blood collection.&#xD;
&#xD;
         21. Workers engaged in conditions requiring long-term exposure to radioactivity; or have&#xD;
             significant radiation exposure (≥2 chest/abdomen CT, or ≥3 other types of X-ray&#xD;
             examinations) within 1 year before the test or have participated inthe&#xD;
             radiopharmaceutical labeling test.&#xD;
&#xD;
         22. Having family planning during the trial period and within 12 months after the last use&#xD;
             of the drug, or not agreeing that subjects and their spouses should take strict&#xD;
             contraceptive measures during the trial period and within 12 months after the last use&#xD;
             of the drug.&#xD;
&#xD;
         23. Those who have lost blood or donated up to 400 mL within 3 months before the screening&#xD;
             period, or those who have received blood transfusion, or those who plan to donate&#xD;
             blood within 3 month after the end of this test.&#xD;
&#xD;
         24. As determined by the investigator, the subject has other factors that are not suitable&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liyan Miao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>liyan Miao, MD</last_name>
    <phone>0512-67972858</phone>
    <email>miaolysuzhou@163.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

